Semanat vs Ozempic: Comparison Guide

Semanat vs Ozempic: Comparison Guide

If you are comparing Semanat and Ozempic, the important point is that Semanat is a real semaglutide brand in India, not just a misspelling of the active ingredient.

This guide compares the products using the correct India-market context so you can better verify a prescription or discuss options with your doctor. Consult your healthcare provider before starting any medication.

What is Ozempic?

Ozempic is Novo Nordisk's brand for semaglutide, a GLP-1 receptor agonist used in adults with type 2 diabetes and widely discussed because semaglutide can also reduce appetite and support weight change.

Ozempic is generally known as a once-weekly injection.

What is Semanat?

Semanat is a Natco semaglutide brand in India. Natco launched SEMANAT alongside SEMAFULL on 21 March 2026, just after India's semaglutide patent expired, for adults with type 2 diabetes whose blood sugar is not sufficiently controlled, alongside diet and exercise.

That means Semanat should not be treated merely as a spelling error or as the active ingredient itself.

What they have in common

Semanat and Ozempic are both tied to semaglutide.

That means both are discussed in relation to:

• improved glucose control in type 2 diabetes
• slower gastric emptying
• reduced appetite in many users
• clinician-guided semaglutide dosing plans

Key differences: Semanat vs Ozempic

1. Brand and company context

• Ozempic is made by Novo Nordisk.
• Semanat is associated with Natco in India.

2. Product presentation

Ozempic is given from a prefilled pen. Natco launched Semanat as multi-dose vials (2 mg/1.5 ml, 4 mg/3 ml and 8 mg/3 ml), with a pen device announced for April 2026. With a vial, each weekly dose is drawn up with a syringe, so ask for training on measuring your exact dose.

3. Market context

Ozempic is the globally established originator semaglutide brand. Semanat is part of the newer India-market rollout from a domestic company.

4. Evidence base

Large semaglutide trial data are tied mainly to the broader originator evidence base, but clinicians still use that evidence when discussing Semanat alongside local product details.

Side effects and safety

Because both are semaglutide-based, the expected side-effect profile is broadly similar. Common effects may include:

• nausea
• vomiting
• diarrhoea
• constipation
• abdominal discomfort
• lower appetite

Less common but serious risks include pancreatitis, gallbladder problems, dehydration leading to kidney problems, and low blood sugar when semaglutide is used with insulin or a sulfonylurea. Semaglutide must not be used if you or a family member has had medullary thyroid carcinoma (MTC), or if you have MEN 2. Get urgent medical help for severe, persistent stomach pain that may spread to your back, or vomiting that stops you keeping fluids down.

Bottom line

Semanat and Ozempic are both semaglutide-based prescription products. The practical comparison is about brand, presentation, and local access—Natco's Semanat in India versus Novo Nordisk's Ozempic—not about brand name versus ingredient confusion.

A clinician can help you compare dosing workflow, refill access, and suitability for your treatment plan. Consult your healthcare provider before starting any medication.

Sources

• https://www.indianpharmapost.com/news/lite/natco-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-affordable-price-of-rs-1290-19427
• https://medicaldialogues.in/news/industry/pharma/indias-semaglutide-market-set-for-generic-boom-as-patents-expire-over-50-brands-lined-up-for-launch-see-full-list-165838
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• https://cdsco.gov.in/opencms/opencms/en/Home/
• https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• https://medlineplus.gov/druginfo/meds/a618008.html